Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Barratt Redrow

(Sharecast News) - Analysts at Berenberg lowered their target price on housebuilder Barratt Redrow from 540.0p to 485.0p on Wednesday following the group's FY25 trading update a day earlier. Berenberg said FY25 has proven to be "a more challenging than expected year" for Barratt Redrow, with housing market headwinds persisting and, although it delivered an FY25 result in line with expectations, the impact was felt on reduced expectations for FY26.

The German bank pointed out that Barratt Redrow said it had seen "some improvement" in the mortgage market, but acknowledged that underlying private sales activity "has remained sensitive to consumer caution". On its conference call, Barratt Redrow said price growth was below 1%, while build-cost inflation was flat in FY25 and was expected to rise to 1-2% in FY26.

However, with "a robust balance sheet" and further synergies to be garnered from the Redrow integration, Berenberg thinks that the group remains well-positioned for when "a more favourable market environment" emerges.

Berenberg, which reiterated its 'hold' rating on the stock, also noted that Barratt Redrow trades on 12x earnings per share and 0.8x tangible net asset values.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.